The Dominantly Inherited Alzheimer Network (DIAN) Observational Study enables researchers around the world to monitor and identify changes in individuals who carry one of the gene mutations (Presenilin1, Presenilin2 or APP) known to cause dominantly inherited Alzheimer’s disease (DIAD).
There is currently no treatment that can prevent or delay the progression of AD, and no new treatments have been approved in over ten years. DIAN aims to define the natural history of AD and establish reliable biomarkers that track with disease.
Our Goal
Research suggests that brain changes may occur years before actual Alzheimer’s symptoms are detected. DIAN evaluates participants at entry and longitudinally thereafter with standardized clinical and cognitive testing, brain imaging, and biological fluid collection (blood, cerebrospinal fluid) with the goal of determining the sequence of changes in pre-symptomatic gene carriers who are destined to develop AD. Another goal is to establish a research database and tissue repository to support research by other investigators around the world. Knowledge gained from the Observational Study may lead to therapeutic options to detect and treat DIAD at its earliest stages — or prevent it all together.
How & Why to Participate
Now enrolling biological adult children of a parent with a mutated gene known to cause DIAD.
Procedures
Enrolled individuals will visit a study site in person and participate in these procedures.
Recent Publications
Optional feed here… List most recent pubs, and/or link to NIH
DIAN Observational Study Support
Randall Bateman, MD
Principal Investigator & Program Director
- Phone: 314-286-1674
- Email: batemanr@wustl.edu
Celeste Karch, PhD
Associate Director & Scientific Director
- Phone: 314-747-3161
- Email: karchc@wustl.edu
Study Team? | Funding | Subcontractors
For Investigators
Visit Investigator Resources for information on accessing resources and participation policies.